Drugs / PCV21 vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06824181 | Feb 2025 → Sep 2027 expected | — | Sanofi | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-06-29 | Sanofi | Results Press Release: Vaccines R&D pipeline raises the bar in RSV, influenza, meningitis, and pneumococcal disease sanofi.com ↗
with positive safety and immunogenicity of the first PCV21 vaccine |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2023-06-29 | Sanofi | Press Release: Vaccines R&D pipeline raises the bar in RSV, influenza, meningitis, and pneumococcal disease sanofi.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PCV21 vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06824181 ↗ |
| Modality | Vaccine | “pneumococcal conjugate vaccine PCV21” NCT06824181 ↗ |
| Route | Intramuscular | “Route of administration:Intramuscular” NCT06824181 ↗ |